 IRVINE, CA ACCESSWIRE January 8, 2020 Hancock Jaffe Laboratories, Inc. HJLI, a developer of medical devices that restore cardiac and vascular health, today announced positive results from its six 6 month CoreoGraft animal feasibility study. At thirty 30, ninety 90, and one hundred and eighty 180 days post CoreoGraft bypass surgeries, all grafts were patent open when the implantations went smoothly and there were no technical errors. At the conclusion of the study, pathology examinations of the grafts and surrounding tissue showed no signs of thrombosis, infection, aneurysmal degeneration, changes in the lumen or other problems that are known to plague saphenous vein grafts SVGs. 